27 min read
Keypoint Newsletter: Welcoming the New Fellows Class of 2024
Keystone Symposia is pleased to introduce the Keystone Symposia Fellows Class of 2024! This year we welcome seven...
David Soto-Pantoja, PhD, investigates cell surface receptor CD47 as an immunotherapy for breast, lung, head and neck cancers and melanoma. Through clinical trials and animal model collaborations, he explores the effects of CD47 targeting on tumor cell bioenergetics, with the goal of developing anti-cancer therapeutics that inhibit tumor growth and prevent chemotherapy-related cardiac toxicity.
Research Area(s):
Research Keywords:
Mentor: Juanita L. Merchant, MD, PhD
Dec 4, 2023 by Keystone Symposia
Keystone Symposia is pleased to introduce the Keystone Symposia Fellows Class of 2024! This year we welcome seven...
Sep 6, 2023 by Keystone Symposia
Established in 2009, Keystone Symposia’s Fellows Program has become a premier professional advancement opportunity for...